Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Development of an Advanced Retinal Imaging System


技術優勢

Non-invasive –A non-invasive instrument for detection of early stage DR and AMD High Resolution –Design provides high imaging speed and localization precision Early Detection –DR and AMD can be treated before irreversible damage occurs More informative –Capable of providing comprehensive physiological information Large patient pool –DR numbers continue to rise; earlier detection is essential for positive outcomes


技術應用

Retinal diseases are the major cause of blindness in developed countries. The accurate diagnosis andmanagement of retinal diseases is highly depend on non‐invasive imaging techniques. Currently, there isno ophthalmic imaging modality suitable for early detection of DR and AMD through quantitative sO2 andRPE imaging. The American Diabetes Association tallied 25.8 million people with diabetes in the UnitedStates in 2011 and many of them are at risk to develop DR. According to the U.S. Centers for DiseaseControl and Prevention, about 5 million people are affected by DR with new cases increasing at 8% eachyear. Up to 50% of patients are not getting their eyes examined or are diagnosed too late for effectivetreatment. DR is the leading cause of blindness in adults aged 20-74 in the U.S. The CDC estimates that1.8 million Americans over age 40 are affected by AMD, and it is expected to reach 2.95 million in 2020.These large populations represent a significant patient pool that would benefit greatly from more routineand reliable testing for early stage DR or AMD. Other potential applications include diseases that can be diagnosed through morphology and function ofthe retinal vessels such as stroke, Alzheimer’s disease, and hypertensive retinopathy. There is also apotential use in the study of glaucoma in which OCT is utilized to diagnose central retinal vein occlusion.


詳細技術說明

This diagnostic device enables tests for early stagedetection of diabetic retinopathy (DR) and age-relatedmacular degeneration (AMD) through in vivo non‐invasiveimaging of retinal sO2 measurement and retinal pigmentepithelium imaging. The device integrates three imagingmodalities: photoacoustic ophthalmoscopy (PAOM), opticalcoherence tomography (OCT), and auto-fluorescence (AF)on a slit lamp bio‐microscope. Visual and quantitative datais collected in one pass and presented in an integrated viewfor research or diagnostic use.


申請號碼

Slides


國家/地區

美國

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版